For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Intermune, Inc.

USPTO Granted Patents = 52

CIPO Patents = 12

EPO Patents = 22

Trademarks = 2

Forward Citations = 499

Loading Chart...

Loading Chart...

57 inventors (with patents filed for the assignee):

Scott D Seiwert (23 out of 26 patents)

Williamson Ziegler Bradford (16 out of 17 patents)

Lawrence M Blatt (13 out of 24 patents)

4. Leonid Beigelman (11 out of 224 patents)

5. Javier Szwarcberg (11 out of 11 patents)

6. Brad Owen Buckman (9 out of 47 patents)

7. Ramachandran Radhakrishnan (9 out of 24 patents)

8. Karl Kossen (9 out of 10 patents)

9. Vladimir Serebryany (8 out of 16 patents)

10. John Beamond Nicholas (7 out of 11 patents)

11. Kumaraswamy Emayan (7 out of 10 patents)

12. Johnnie Y Ramphal (6 out of 6 patents)

13. Steven Wade Andrews (6 out of 97 patents)

14. April L Kennedy (5 out of 10 patents)

15. Timothy S Kercher (4 out of 30 patents)

Core Competencies:

Anti-Fibrotic Pyridinones

Pirfenidone Therapy

Inflammatory Disorders

Fibrotic Disorders

Hepatitis C Virus Replication

Stress-Activated Protein Kinase

Microvascular Integrity

Capsule Formulation

Lysophosphatidic Acid Receptor Antagonists

Macrocyclic Inhibitors

Alpha-Glucosidase Inhibitors

Peptide Inhibitors

52 patents: Sort by Forward Citations

1. 10898474 - Anti-fibrotic pyridinones (2021-01-26),

2. 10544161 - Anti-fibrotic pyridinones (2020-01-28),

3. 10376497 - Anti-fibrotic pyridinones (2019-08-13),

4. 10233195 - Anti-fibrotic pyridinones (2019-03-19),

5. RE47142 - Compounds and methods for treating inflammatory and fibrotic disorders (2018-11-26),

6. 10010536 - Method of modulating stress-activated protein kinase system (2018-07-03),

7. 9726677 - Proteomic IPF markers (2017-08-08),

8. 9682071 - Methods of improving microvascular integrity (2017-06-20),

9. 9675593 - Anti-fibrotic pyridinones (2017-06-13),

10. 9561217 - Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone (2017-02-07),

11. 9527816 - Method of modulating stress-activated protein kinase system (2016-12-27),

12. 9359379 - Anti-fibrotic pyridinones (2016-06-07),

13. 9290450 - Compounds and methods for treating inflammatory and fibrotic disorders (2016-03-22),

14. 9017722 - Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone (2015-04-28),

15. 8975235 - Lysophosphatidic acid receptor antagonists (2015-03-10),

Intermune, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of respiratory and orphan fibrotic diseases. With a commitment to improving the lives of patients, Intermune invests in research and development to bring novel medicines to market. Visit their website to learn more about their advanced therapies and ongoing clinical trials.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

52 Patents

#24 in South San Francisco, CA

#1,546 in California

#6,539 in US

#13,160 in the World

South San Francisco, CA, United States of America

Intermune, Inc.

Forward Citations = 499

57 inventors:

Scott D Seiwert (23 out of 26 patents)

Williamson Ziegler Bradford (16 out of 17 patents)

Lawrence M Blatt (13 out of 24 patents)

4. Leonid Beigelman (11 out of 224 patents)

5. Javier Szwarcberg (11 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…